CY1111858T1 - Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων - Google Patents

Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων

Info

Publication number
CY1111858T1
CY1111858T1 CY20111100920T CY111100920T CY1111858T1 CY 1111858 T1 CY1111858 T1 CY 1111858T1 CY 20111100920 T CY20111100920 T CY 20111100920T CY 111100920 T CY111100920 T CY 111100920T CY 1111858 T1 CY1111858 T1 CY 1111858T1
Authority
CY
Cyprus
Prior art keywords
receptor modulators
opioid receptor
heterocyclic derivatives
opioid
disorders
Prior art date
Application number
CY20111100920T
Other languages
English (en)
Inventor
Henry J Breslin
Wei He
Robert W Kavash
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1111858T1 publication Critical patent/CY1111858T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέες ενώσεις ως διαμορφωτές, ανταγωνιστές, και αγωνιστές υποδοχέα οπιοειδών χρήσιμες για τη θεραπευτική αγωγή διαμορφούμενων από οπιοειδή διαταραχών όπως άλγος και γαστρεντερικές διαταραχές.
CY20111100920T 2002-04-29 2011-09-22 Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων CY1111858T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37640602P 2002-04-29 2002-04-29
US10/400,006 US7041681B2 (en) 2002-04-29 2003-03-26 Compounds as opioid receptor modulators
EP03719805A EP1499313B1 (en) 2002-04-29 2003-04-17 Heterocyclic derivatives as opioid receptor modulators

Publications (1)

Publication Number Publication Date
CY1111858T1 true CY1111858T1 (el) 2015-11-04

Family

ID=29406753

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100920T CY1111858T1 (el) 2002-04-29 2011-09-22 Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων

Country Status (23)

Country Link
US (3) US7041681B2 (el)
EP (2) EP1499313B1 (el)
JP (1) JP4969039B2 (el)
KR (2) KR101377078B1 (el)
CN (2) CN101255131B (el)
AT (1) ATE514425T1 (el)
AU (3) AU2003223664A1 (el)
BR (1) BRPI0309708B1 (el)
CA (3) CA2483662C (el)
CY (1) CY1111858T1 (el)
DK (1) DK1499313T3 (el)
ES (2) ES2366471T3 (el)
HR (2) HRP20041014B1 (el)
HU (1) HUE031331T2 (el)
IL (2) IL164910A (el)
MX (1) MXPA04011947A (el)
NO (3) NO332722B1 (el)
NZ (2) NZ575640A (el)
PL (2) PL219912B1 (el)
PT (1) PT1499313E (el)
RU (1) RU2332411C2 (el)
SI (1) SI1499313T1 (el)
WO (1) WO2003092688A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
ES2533176T3 (es) 2004-03-15 2015-04-08 Janssen Pharmaceutica Nv Proceso para preparar intermedios de compuestos útiles como moduladores de receptores opioides
EP1863764A1 (en) * 2005-03-14 2007-12-12 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators
DE102005050497A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
WO2008021851A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
CA2779083C (en) * 2009-10-30 2017-07-04 Peter J. Connolly Pyrazines as delta opioid receptor modulators
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
WO2017039778A1 (en) * 2015-08-31 2017-03-09 Regents Of The University Of Minnesota Opioid receptor modulators and use thereof
EP3521301B1 (en) 2016-09-27 2024-03-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Polyamide compound and use thereof
CN106866463B (zh) * 2017-01-24 2018-08-28 富乐马鸿凯（大连）医药有限公司 艾沙度林中间体的制备方法
CA3018321A1 (en) 2017-09-25 2019-03-25 Apotex Inc. Novel crystalline form of eluxadoline

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE584914A (el) 1958-11-24
CH543479A (de) 1970-05-06 1973-10-31 Hoffmann La Roche Verfahren zur Herstellung von Phenyläthylaminderivaten
GB2146026A (en) 1983-09-07 1985-04-11 Tanabe Seiyaku Co Peptides and process for preparing the same
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
JPH05339240A (ja) 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
FR2735776B1 (fr) 1995-06-22 1997-07-18 Synthelabo Derives de 2,3-dihydro-1h-indole, leur preparation et leur application en therapeutique
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6916905B2 (en) * 2000-03-24 2005-07-12 The United States Of America As Represented By The Department Of Health And Human Services Dmt-Tic di-and tri-peptidic derivatives and related compositions and methods of use
EA006443B1 (ru) 2000-10-30 2005-12-29 Янссен Фармацевтика Н.В. Ингибиторы трипептидил пептидазы
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
EP1863764A1 (en) * 2005-03-14 2007-12-12 Janssen Pharmaceutica, N.V. Process for the preparation of opioid modulators

Also Published As

Publication number Publication date
NZ575640A (en) 2010-10-29
NO20045159L (no) 2004-11-25
CA2483662C (en) 2011-12-06
IL164910A0 (en) 2005-12-18
NO335607B1 (no) 2015-01-12
US7659402B2 (en) 2010-02-09
ES2608840T3 (es) 2017-04-17
NO20120788L (no) 2004-11-25
AU2011202364A1 (en) 2011-06-09
RU2332411C2 (ru) 2008-08-27
CA2483662A1 (en) 2003-11-13
MXPA04011947A (es) 2005-07-26
AU2009233679A1 (en) 2009-11-26
ATE514425T1 (de) 2011-07-15
PT1499313E (pt) 2011-08-24
HRP20041014B1 (hr) 2013-10-11
HRP20041014A2 (en) 2005-06-30
US7202381B2 (en) 2007-04-10
US20050187252A1 (en) 2005-08-25
KR101287409B1 (ko) 2013-07-19
PL219912B1 (pl) 2015-07-31
SI1499313T1 (sl) 2011-10-28
CN1665501A (zh) 2005-09-07
KR101377078B1 (ko) 2014-03-25
EP1499313B1 (en) 2011-06-29
EP2275105A1 (en) 2011-01-19
HUE031331T2 (hu) 2017-07-28
IL197642A (en) 2015-04-30
NO20140530L (no) 2004-11-25
PL396160A1 (pl) 2012-01-16
AU2009233679B2 (en) 2011-05-26
US20060030558A1 (en) 2006-02-09
RU2004131829A (ru) 2005-05-27
CA2883629A1 (en) 2003-11-13
NZ561795A (en) 2009-04-30
IL197642A0 (en) 2009-12-24
CA2753371C (en) 2015-06-30
CN1665501B (zh) 2010-10-06
ES2366471T3 (es) 2011-10-20
WO2003092688A2 (en) 2003-11-13
US20040010014A1 (en) 2004-01-15
AU2011202364B2 (en) 2012-09-20
EP2275105B1 (en) 2016-10-05
WO2003092688A3 (en) 2004-08-19
JP2005530749A (ja) 2005-10-13
KR20040104663A (ko) 2004-12-10
PL374053A1 (en) 2005-09-19
BRPI0309708B1 (pt) 2017-03-21
EP1499313A2 (en) 2005-01-26
NO332722B1 (no) 2012-12-27
DK1499313T3 (da) 2011-10-03
US7041681B2 (en) 2006-05-09
CN101255131B (zh) 2012-12-05
KR20130041301A (ko) 2013-04-24
JP4969039B2 (ja) 2012-07-04
CN101255131A (zh) 2008-09-03
IL164910A (en) 2011-07-31
HRP20130893A2 (hr) 2014-02-28
CA2753371A1 (en) 2003-11-13
AU2003223664A1 (en) 2003-11-17
BR0309708A (pt) 2005-02-15
PL211163B1 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
CY1111858T1 (el) Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
NO20072971L (no) Potentiatorer av glutamatreceptorer
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
CY1110362T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ητ6 υποδοχεα
CY1105705T1 (el) Παραγωγα ινδολυλαλκυλαμινης σαν συνδετηρες 5-υδροξυτρυπταμινης-6
ATE486071T1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
UA87962C2 (ru) Соединения как модуляторы опиоидного рецептора
EA200600416A1 (ru) Производные циклопропила в качестве антагонистов рецептора nk3
SE0303488D0 (sv) New use 1X